Abaloparatide
Clinical data | |
---|---|
Trade names | Tymlos |
Other names | BA058, BIM-44058 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a617038 |
License data | |
Subcutaneous injection | |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
JSmol) | |
| |
|
Abaloparatide, sold under the brand name Tymlos among others, is a
The most common side effects include
Abaloparatide was approved for medical use in the United States in April 2017,[1][4][5][6][7] and in the European Union in December 2022.[2]
Medical uses
Abaloparatide is
In the US it is also indicated for the treatment to increase bone density in men with osteoporosis at high risk of fracture or in people who have failed or are intolerant to other available osteoporosis therapy.[1][8]
Side effects
The most common side effects reported by more than 2% of clinical trials subjects are hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain and vertigo.[1]
Preclinical studies revealed that abaloparatide systemic daily administration leads to a dose- and time-dependent increase in the incidence of osteosarcoma in rodents.[9] It is unknown if abaloparatide will cause osteosarcoma in humans.[1]<
Pharmacology
Abaloparatide is 34 amino acid synthetic analog of
History
Preclinical studies
Abaloropatide was invented at Ipsen.[13] It was known as BIM-44058 during pre-clinical studies and as BA058 while under clinical development. The anabolic effects of abaloparatide on bone were demonstrated in two preclinical studies conducted in ovariectomized rats. Both studies showed increased cortical and trabecular bone volume and density, and trabecular microarchitecture improvement in vertebral and nonvertebral bones after short-term[14] and long-term[15] daily subcutaneous injection of abaloparatide compared to controls. Recent studies indicated a dose-dependent increased in bone mass and strength in long-term abalorapatide treatment.[16]
Clinical Trials
Phase II trials were initiated in 2008. A 24-week randomized trial was conducted in postmenopausal women with osteoporosis (n=222) assessing
In the phase III (2011-2014) Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) trial, an 18-months randomized, multicenter, double-blinded, placebo-controlled study evaluated the long-term efficacy of abaloparatide compared to placebo and teriparatide in 2,463 postmenopausal women (± 69 years old).[19] Women who received daily injections of abaloparatide experienced substantial reduction in the incidence of fractures compared to placebo. Additionally, greater BMD increase at 6, 12 and 18 months in spinal, hips and femoral bones was observed in abaloparatide compared to placebo and teriparatide-treated subjects.[20]
Participants who completed 18 months of abaloparatide or placebo in the ACTIVE study were invited to participate in an extended open-labeled study - ACTIVExtend study (2012-2016).
A clinical trial assessing the effectiveness of abaloparatide in altering spinal bone mineral density (BMD) in male subjects is expected to start in the first quarter of 2018. If successful, Radius Health aims to submit a sNDA to expand the use of abaloparatide-SC to treat men with osteoporosis.[23]
In addition to the injectable form of abaloparatide, a transdermal patch is also in development.[3]
Society and culture
Legal status
Radius Health filed a
In February 2016 a NDA was filed to the FDA, Radius NDA for abaloparatide-SC was accepted in May 2016.[25] A Prescription Drug User Fee Act (PDUFA) date was initially granted on 30 March 2016, but then extended to 30 June 2017.[26]
On 13 October 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Eladynos, intended for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.[27] The applicant for this medicinal product is Radius Health Ireland Ltd.[27] Abaloparatide was approved for medical use in the European Union in December 2022.[2][28]
Intellectual Property
Radius Health holds three patents on abaloparatide-SC, with expiration dates from 2027 to 2028.[29] The patents relate to the drug composition (US 8148333), and the drug delivery methods (US 7803770 B2 and US 8748382-B2).
Economics
A major contributor to this section appears to have a close connection with its subject. (November 2020) |
Abaloparatide-SC is manufactured by Radius Health, Inc, a biomedical company based in Boston, Massachusetts.[23] The firm reported that sales for abaloparatide were $3.5 million for the third quarter of 2017.[23]
In July 2017, Radius Health licensed rights to Teijin Limited for abaloparatide-SC manufacture and commercialization in Japan. Teijin is developing abaloparatide-SC under agreement with Ipsen Pharma S.A.S., and is conducting a phase III clinical trial in Japanese patients with osteoporosis.[30]
References
- ^ a b c d e f g "Tymlos- abaloparatide injection, solution". DailyMed. 28 December 2021. Retrieved 14 October 2022.
- ^ a b c d e f "Eladynos EPAR". European Medicines Agency. 12 October 2022. Retrieved 3 March 2023.
- ^ a b Spreitzer H (18 January 2016). "Neue Wirkstoffe – Abaloparatid". Österreichische Apothekerzeitung (in German) (2/2016): 12.
- ^ "Tymlos Subcutaneous Injection". accessdata.fda.gov. 8 June 2017. Retrieved 14 October 2022.
- ^ a b "Drug Trial Snapshot: Tymlos". U.S. Food and Drug Administration (FDA). 9 February 2019. This article incorporates text from this source, which is in the public domain.
- ^ "FDA Approves Radius Health's Tymlos (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture" (Press release). Radius Inc. 28 April 2017. Archived from the original on 4 November 2017. Retrieved 3 November 2017.
- ^ "FDA Approves Radius Health's Tymlos (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture" (Press release). Radius Health. 28 April 2017. Retrieved 3 March 2023 – via GlobeNewswire.
- ^ "Radius Health's Tymlos (abaloparatide) Receives U.S. FDA Approval as a Treatment to Increase Bone Density in Men with Osteoporosis at High Risk for Fracture". Radius (Press release). 21 December 2022. Retrieved 3 March 2023.
- PMID 28389324.
- PMID 28680788.
- PMID 19674967.
- PMID 29049872.
- ^ US Patent US 6,544,949 B1, "Analogs of Parathyroid Hormone", 8 April 2003, Inventor: Zheng Xin Dong
- PMID 27395059.
- PMID 27748532.
- PMID 27894941.
- ^ Clinical trial number NCT00542425 for "Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis" at ClinicalTrials.gov
- PMID 25393645.
- ^ Clinical trial number NCT01343004 for "Phase III Study to Evaluate the Safety and Efficacy of BA058 for Prevention of Fracture in Postmenopausal Women" at ClinicalTrials.gov
- PMID 27533157.
- ^ Clinical trial number NCT01657162 for "Twenty Four Month Extension Study of BA058-05-003" at ClinicalTrials.gov
- PMID 28160873.
- ^ a b c d "Radius Health Reports Third Quarter 2017 Financial and Operating Results and Provides Business Update" (Press release). Radius Health. 2 November 2017. Retrieved 3 November 2017 – via GlobeNewswire.
- ^ "Radius Health Has Submitted a Marketing Authorization Application for the Investigational Drug Abaloparatide-SC for the Treatment of Postmenopausal Osteoporosis in Europe" (Press release). Retrieved 3 November 2017.
- ^ "Radius Announces FDA Acceptance for Filing of New Drug Application for Abaloparatide-SC for the Treatment of Postmenopausal Women with Osteoporosis" (Press release). Retrieved 4 November 2017.
- ^ "NDA Approval Letter". FDA. 27 April 2017.
- ^ a b "Eladynos: Pending EC decision". European Medicines Agency. 13 October 2022. Archived from the original on 14 October 2022. Retrieved 14 October 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Eladynos Product information". Union Register of medicinal products. Retrieved 3 March 2023.
- ^ "Abaloparatide". PharmaCompass.com. Retrieved 3 November 2017.
- ^ "Radius Health Announces License and Development Agreement for Abaloparatide-SC with Teijin Limited in Japan" (Press release). Retrieved 3 November 2017.